Revolutionizing Alzheimer's disease and clinical trials through biomarkers
Abstract The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subject...
Gespeichert in:
| Veröffentlicht in: | Alzheimer's & dementia : diagnosis, assessment & disease monitoring assessment & disease monitoring, 2015-12, Vol.1 (4), p.412-419 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 419 |
|---|---|
| container_issue | 4 |
| container_start_page | 412 |
| container_title | Alzheimer's & dementia : diagnosis, assessment & disease monitoring |
| container_volume | 1 |
| creator | Mattsson, Niklas Carrillo, Maria C Dean, Robert A Devous, Michael D Nikolcheva, Tania Pesini, Pedro Salter, Hugh Potter, William Z Sperling, Reisa S Bateman, Randall J Bain, Lisa J Liu, Enchi |
| description | Abstract The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clinical trials, there is a clear need to develop novel biomarkers that are minimally invasive and that more broadly characterize underlying pathogenic mechanisms, including neurodegeneration, neuroinflammation, and synaptic dysfunction. These may include blood-based assays and new neuropsychological testing protocols, as well as novel ligands for positron emission tomography imaging, and advanced magnetic resonance imaging methodologies. In addition, there is a need for biomarkers that can serve as theragnostic markers of response to treatment. Standardization remains a challenge, although international consortia have made substantial progress in this area and provide lessons for future standardization efforts. |
| doi_str_mv | 10.1016/j.dadm.2015.09.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_504855</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S2352872915000718</els_id><sourcerecordid>1792775173</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5631-78a46ab66be0e349db0fce6647534ca009eed30c92fc2ee61f9697aeaa2b55033</originalsourceid><addsrcrecordid>eNqNkk1v1DAQhiMEolXpH-CAcoNLwtiJ4_iCtLR8VUVIfJxHjjPZ9W4-ip1stf31OMq2am9cbGvmnXdGfiaKXjNIGbDi_Tatdd2lHJhIQaUA7Fl0yjPBk1Jy9fzR-yQ6934LQZErnjN4GZ1wyTMlOD-Nrn7Sfmin0Q69vbP9Ol61dxuyHbm3Pq6tJ-0p1n0dm9b21ug2Hp3VrY_HjRum9Sau7NBptyPnX0UvmpCh8-N9Fv35_On3xdfk-seXbxer68SIImOJLHVe6KooKgLKclVX0BgqilyKLDcaQBHVGRjFG8OJCtaoQklNWvNKCMiysyhZfP0t3UwV3jgbJjjgoC0eQ7vwIhSQl0IE_YdFHzId1Yb60en2SdnTTG83uB72mJdS5SULBu-OBm74O5EfsbPeUNvqnobJI5OKSymYnGfji9S4wXtHzUMbBjhzwy3O3HDmhqAwUAlFbx4P-FByTykIPi6CW9vS4T8s8XJ1ya_C8X0Oglq6HL-BApu9JYf3SHd0IL8dJtcHbMjQcwT8Ne_PvD6hHkCyMvsHgCi_1w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1792775173</pqid></control><display><type>article</type><title>Revolutionizing Alzheimer's disease and clinical trials through biomarkers</title><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>SWEPUB Freely available online</source><source>Wiley Online Library Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Mattsson, Niklas ; Carrillo, Maria C ; Dean, Robert A ; Devous, Michael D ; Nikolcheva, Tania ; Pesini, Pedro ; Salter, Hugh ; Potter, William Z ; Sperling, Reisa S ; Bateman, Randall J ; Bain, Lisa J ; Liu, Enchi</creator><creatorcontrib>Mattsson, Niklas ; Carrillo, Maria C ; Dean, Robert A ; Devous, Michael D ; Nikolcheva, Tania ; Pesini, Pedro ; Salter, Hugh ; Potter, William Z ; Sperling, Reisa S ; Bateman, Randall J ; Bain, Lisa J ; Liu, Enchi</creatorcontrib><description>Abstract The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clinical trials, there is a clear need to develop novel biomarkers that are minimally invasive and that more broadly characterize underlying pathogenic mechanisms, including neurodegeneration, neuroinflammation, and synaptic dysfunction. These may include blood-based assays and new neuropsychological testing protocols, as well as novel ligands for positron emission tomography imaging, and advanced magnetic resonance imaging methodologies. In addition, there is a need for biomarkers that can serve as theragnostic markers of response to treatment. Standardization remains a challenge, although international consortia have made substantial progress in this area and provide lessons for future standardization efforts.</description><identifier>ISSN: 2352-8729</identifier><identifier>EISSN: 2352-8729</identifier><identifier>DOI: 10.1016/j.dadm.2015.09.001</identifier><identifier>PMID: 27239522</identifier><language>eng</language><publisher>United States: Elsevier</publisher><subject>Alzheimer's disease ; Amyloid ; Biomarkers ; Blood biomarkers ; Cerebrospinal fluid ; Clinical trials ; CSF ; Diagnostic Assessment & Prognosis ; Imaging ; MRI ; Neurology ; Other ; PET ; Tau</subject><ispartof>Alzheimer's & dementia : diagnosis, assessment & disease monitoring, 2015-12, Vol.1 (4), p.412-419</ispartof><rights>The Authors</rights><rights>2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.</rights><rights>2015 The Authors 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5631-78a46ab66be0e349db0fce6647534ca009eed30c92fc2ee61f9697aeaa2b55033</citedby><cites>FETCH-LOGICAL-c5631-78a46ab66be0e349db0fce6647534ca009eed30c92fc2ee61f9697aeaa2b55033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879481/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879481/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,550,723,776,780,860,881,1411,11542,27903,27904,45553,45554,46031,46455,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27239522$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:227239522$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Mattsson, Niklas</creatorcontrib><creatorcontrib>Carrillo, Maria C</creatorcontrib><creatorcontrib>Dean, Robert A</creatorcontrib><creatorcontrib>Devous, Michael D</creatorcontrib><creatorcontrib>Nikolcheva, Tania</creatorcontrib><creatorcontrib>Pesini, Pedro</creatorcontrib><creatorcontrib>Salter, Hugh</creatorcontrib><creatorcontrib>Potter, William Z</creatorcontrib><creatorcontrib>Sperling, Reisa S</creatorcontrib><creatorcontrib>Bateman, Randall J</creatorcontrib><creatorcontrib>Bain, Lisa J</creatorcontrib><creatorcontrib>Liu, Enchi</creatorcontrib><title>Revolutionizing Alzheimer's disease and clinical trials through biomarkers</title><title>Alzheimer's & dementia : diagnosis, assessment & disease monitoring</title><addtitle>Alzheimers Dement (Amst)</addtitle><description>Abstract The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clinical trials, there is a clear need to develop novel biomarkers that are minimally invasive and that more broadly characterize underlying pathogenic mechanisms, including neurodegeneration, neuroinflammation, and synaptic dysfunction. These may include blood-based assays and new neuropsychological testing protocols, as well as novel ligands for positron emission tomography imaging, and advanced magnetic resonance imaging methodologies. In addition, there is a need for biomarkers that can serve as theragnostic markers of response to treatment. Standardization remains a challenge, although international consortia have made substantial progress in this area and provide lessons for future standardization efforts.</description><subject>Alzheimer's disease</subject><subject>Amyloid</subject><subject>Biomarkers</subject><subject>Blood biomarkers</subject><subject>Cerebrospinal fluid</subject><subject>Clinical trials</subject><subject>CSF</subject><subject>Diagnostic Assessment & Prognosis</subject><subject>Imaging</subject><subject>MRI</subject><subject>Neurology</subject><subject>Other</subject><subject>PET</subject><subject>Tau</subject><issn>2352-8729</issn><issn>2352-8729</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>D8T</sourceid><recordid>eNqNkk1v1DAQhiMEolXpH-CAcoNLwtiJ4_iCtLR8VUVIfJxHjjPZ9W4-ip1stf31OMq2am9cbGvmnXdGfiaKXjNIGbDi_Tatdd2lHJhIQaUA7Fl0yjPBk1Jy9fzR-yQ6934LQZErnjN4GZ1wyTMlOD-Nrn7Sfmin0Q69vbP9Ol61dxuyHbm3Pq6tJ-0p1n0dm9b21ug2Hp3VrY_HjRum9Sau7NBptyPnX0UvmpCh8-N9Fv35_On3xdfk-seXbxer68SIImOJLHVe6KooKgLKclVX0BgqilyKLDcaQBHVGRjFG8OJCtaoQklNWvNKCMiysyhZfP0t3UwV3jgbJjjgoC0eQ7vwIhSQl0IE_YdFHzId1Yb60en2SdnTTG83uB72mJdS5SULBu-OBm74O5EfsbPeUNvqnobJI5OKSymYnGfji9S4wXtHzUMbBjhzwy3O3HDmhqAwUAlFbx4P-FByTykIPi6CW9vS4T8s8XJ1ya_C8X0Oglq6HL-BApu9JYf3SHd0IL8dJtcHbMjQcwT8Ne_PvD6hHkCyMvsHgCi_1w</recordid><startdate>201512</startdate><enddate>201512</enddate><creator>Mattsson, Niklas</creator><creator>Carrillo, Maria C</creator><creator>Dean, Robert A</creator><creator>Devous, Michael D</creator><creator>Nikolcheva, Tania</creator><creator>Pesini, Pedro</creator><creator>Salter, Hugh</creator><creator>Potter, William Z</creator><creator>Sperling, Reisa S</creator><creator>Bateman, Randall J</creator><creator>Bain, Lisa J</creator><creator>Liu, Enchi</creator><general>Elsevier</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>201512</creationdate><title>Revolutionizing Alzheimer's disease and clinical trials through biomarkers</title><author>Mattsson, Niklas ; Carrillo, Maria C ; Dean, Robert A ; Devous, Michael D ; Nikolcheva, Tania ; Pesini, Pedro ; Salter, Hugh ; Potter, William Z ; Sperling, Reisa S ; Bateman, Randall J ; Bain, Lisa J ; Liu, Enchi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5631-78a46ab66be0e349db0fce6647534ca009eed30c92fc2ee61f9697aeaa2b55033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Alzheimer's disease</topic><topic>Amyloid</topic><topic>Biomarkers</topic><topic>Blood biomarkers</topic><topic>Cerebrospinal fluid</topic><topic>Clinical trials</topic><topic>CSF</topic><topic>Diagnostic Assessment & Prognosis</topic><topic>Imaging</topic><topic>MRI</topic><topic>Neurology</topic><topic>Other</topic><topic>PET</topic><topic>Tau</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mattsson, Niklas</creatorcontrib><creatorcontrib>Carrillo, Maria C</creatorcontrib><creatorcontrib>Dean, Robert A</creatorcontrib><creatorcontrib>Devous, Michael D</creatorcontrib><creatorcontrib>Nikolcheva, Tania</creatorcontrib><creatorcontrib>Pesini, Pedro</creatorcontrib><creatorcontrib>Salter, Hugh</creatorcontrib><creatorcontrib>Potter, William Z</creatorcontrib><creatorcontrib>Sperling, Reisa S</creatorcontrib><creatorcontrib>Bateman, Randall J</creatorcontrib><creatorcontrib>Bain, Lisa J</creatorcontrib><creatorcontrib>Liu, Enchi</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>Alzheimer's & dementia : diagnosis, assessment & disease monitoring</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mattsson, Niklas</au><au>Carrillo, Maria C</au><au>Dean, Robert A</au><au>Devous, Michael D</au><au>Nikolcheva, Tania</au><au>Pesini, Pedro</au><au>Salter, Hugh</au><au>Potter, William Z</au><au>Sperling, Reisa S</au><au>Bateman, Randall J</au><au>Bain, Lisa J</au><au>Liu, Enchi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Revolutionizing Alzheimer's disease and clinical trials through biomarkers</atitle><jtitle>Alzheimer's & dementia : diagnosis, assessment & disease monitoring</jtitle><addtitle>Alzheimers Dement (Amst)</addtitle><date>2015-12</date><risdate>2015</risdate><volume>1</volume><issue>4</issue><spage>412</spage><epage>419</epage><pages>412-419</pages><issn>2352-8729</issn><eissn>2352-8729</eissn><abstract>Abstract The Alzheimer's Association's Research Roundtable met in May 2014 to explore recent progress in developing biomarkers to improve understanding of disease pathogenesis and expedite drug development. Although existing biomarkers have proved extremely useful for enrichment of subjects in clinical trials, there is a clear need to develop novel biomarkers that are minimally invasive and that more broadly characterize underlying pathogenic mechanisms, including neurodegeneration, neuroinflammation, and synaptic dysfunction. These may include blood-based assays and new neuropsychological testing protocols, as well as novel ligands for positron emission tomography imaging, and advanced magnetic resonance imaging methodologies. In addition, there is a need for biomarkers that can serve as theragnostic markers of response to treatment. Standardization remains a challenge, although international consortia have made substantial progress in this area and provide lessons for future standardization efforts.</abstract><cop>United States</cop><pub>Elsevier</pub><pmid>27239522</pmid><doi>10.1016/j.dadm.2015.09.001</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2352-8729 |
| ispartof | Alzheimer's & dementia : diagnosis, assessment & disease monitoring, 2015-12, Vol.1 (4), p.412-419 |
| issn | 2352-8729 2352-8729 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_504855 |
| source | DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; SWEPUB Freely available online; Wiley Online Library Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Alzheimer's disease Amyloid Biomarkers Blood biomarkers Cerebrospinal fluid Clinical trials CSF Diagnostic Assessment & Prognosis Imaging MRI Neurology Other PET Tau |
| title | Revolutionizing Alzheimer's disease and clinical trials through biomarkers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T06%3A16%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Revolutionizing%20Alzheimer's%20disease%20and%20clinical%20trials%20through%20biomarkers&rft.jtitle=Alzheimer's%20&%20dementia%20:%20diagnosis,%20assessment%20&%20disease%20monitoring&rft.au=Mattsson,%20Niklas&rft.date=2015-12&rft.volume=1&rft.issue=4&rft.spage=412&rft.epage=419&rft.pages=412-419&rft.issn=2352-8729&rft.eissn=2352-8729&rft_id=info:doi/10.1016/j.dadm.2015.09.001&rft_dat=%3Cproquest_swepu%3E1792775173%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1792775173&rft_id=info:pmid/27239522&rft_els_id=1_s2_0_S2352872915000718&rfr_iscdi=true |